Clinical Trials Logo

Urinary Urge Incontinence clinical trials

View clinical trials related to Urinary Urge Incontinence.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05543382 Active, not recruiting - Clinical trials for Overactive Bladder Syndrome

Cycling Study With the Axonics System

Start date: August 9, 2022
Phase:
Study type: Observational [Patient Registry]

A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.

NCT ID: NCT05381116 Active, not recruiting - Overactive Bladder Clinical Trials

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

REDUCEOAB
Start date: April 14, 2022
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.

NCT ID: NCT05308979 Active, not recruiting - Overactive Bladder Clinical Trials

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

NCT ID: NCT03556891 Active, not recruiting - Overactive Bladder Clinical Trials

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.